Follow-up | Variable | Readmission | Mortality | ||||
---|---|---|---|---|---|---|---|
Analysis | suPAR† | Events (%)| | OR (95% CI) | P-value | Events (%)| | OR (95% CI) | P-value |
30 days | Continuous | 1.36 (1.0–1.8) | 0.042 | 1.85 (0.8–4.4) | 0.171 | ||
Adjusted | 1st quartile | 35 (12.4%) | 1 | 1 (0.4%) | 1 | ||
2nd quartile | 36 (13.5%) | 1.00 (0.7–1.7) | 0.99 | 2 (0.8%) | N/A§ | ||
3rd quartile | 40 (16.9%) | 1.14 (0.7–1.9) | 0.62 | 1 (0.4%) | 0.34 (0.02–6.4) | 0.47 | |
4th quartile | 78 (27.6%) | 1.96 (1.1–3.3) | 0.014 | 17 (6.0%) | 0.95 (0.08–11.2) | 0.97 | |
Total¶ | 189 (41.8%) | 21 (36.8%) | |||||
90 days | Continuous | 1.26 (1.0–1.6) | 0.08 | 2.79 (1.5–5.3) | 0.0019 | ||
Adjusted | 1st quartile | 63 (22.3%) | 1 | 1 (0.4%) | 1 | ||
2nd quartile | 61 (22.9%) | 1.00 (0.7–1.5) | 0.99 | 2 (0.8%) | N/A§ | ||
3rd quartile | 61 (25.7%) | 1.06 (0.7–1.6) | 0.81 | 6 (2.5%) | 1.63 (0.2–15.8) | 0.67 | |
4th quartile | 104 (36.7%) | 1.58 (1.0–2.5) | 0.049 | 29 (10.2%) | 2.39 (0.3–21.3) | 0.44 | |
Total¶ | 289 (63.9%) | 38 (66.7%) | |||||
365 days‡ | Continuous | 1.27 (1.0–1.6) | 0.052 | 2.94 (1.7–5.1) | 0.0002 | ||
Adjusted | 1st quartile | 105 (37.2%) | 1 | 2 (0.7%) | 1 | ||
2nd quartile | 107 (40.2%) | 1.03 (0.7–1.5) | 0.88 | 4 (1.5%) | 0.19 (0.02–2.3) | 0.19 | |
3rd quartile | 104 (43.9%) | 1.26 (0.8–1.9) | 0.25 | 9 (3.8%) | 1.58 (0.3–8.6) | 0.60 | |
4th quartile | 136 (48.1%) | 1.56 (1.0–2.4) | 0.044 | 42 (14.8%) | 2.75 (0.5–13.9) | 0.22 | |
Total¶ | 452 (100%) | 57 (100%) |